Introduction
• Diseases such as type 2 diabetes mellitus (T2DM) and rheumatoid arthritis (RA) are becoming increasingly prevalent in countries in Asia Pacific. Chronic infections, such as human immunodeficiency virus-1 (HIV-1), hepatitis B virus (HBV) and hepatitis C virus (HCV), are also threats to public health.
• Large numbers of treatments are available for these diseases and infections. However, historically, there has been a delay between the marketing approval of drugs in Western countries and other markets worldwide, such as Asia.
• The objective of this analysis was to investigate patterns of drug approvals in Western and Asian countries in these disease areas.
Conclusion
The average delay between the date of approval of drugs in Asian and Western markets has decreased dramatically over the past 15 years, although this pattern varied between disease areas. However, although faster access to new therapies is apparent, delays to launch in Asian markets are still present.
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Methods
• National drug regulatory authority websites were searched for new drug approval dates in four Asian countries (Japan, 
Results
• Of the 73 drugs studied, more had been approved in the US and EU than in any of the Asian countries studied. Indonesia had the fewest marketing approvals for the included drugs, with only 28 ( Figure 1 ).
• At least one Western and one Asian approval was recorded for 56 drugs out of the 73 included (HBV n=2/2, HCV n=8/9, HIV-1 n=26/32, RA n=9/9 T2DM n=11/21).
• For drugs indicated in RA and T2DM that had marketing approval recorded in ≥1 Western and ≥1 Asian market, there was a strong negative correlation between the date of first approval (in any country) and the delay to marketing approval between the West and Asia (r=-0.72; p<0.001; Spearman Rank correlation; Figure 2A ). This implies that delays between marketing approval in Asia and the West have been reducing over the past 15 years.
Discussion
• The delay between the average date of approval of drugs in Asian and Western markets has decreased dramatically over the past decade, suggesting that patients in Asia now have faster access to new therapies.
*Tenofovir was considered for its first indication only (HIV-1) Figure 1 . Total number of marketing approvals* for the included disease areas from each country/region studied.
-This may have an impact on the future marketing strategies of pharmaceutical companies; to maximise the benefit of an earlier approval date in Asia, there will be a need for earlier or simultaneous drug launches, necessitating a truly global approach to market access. -Whilst there was a relatively strong correlation between the first approval date (in any included country) and the delay between average marketing approval date in the West and Asia for drugs indicated in T2DM or RA, the correlation was weaker when drugs indicated in HIV-1 were analysed. This suggests that there may be variation in the trend in different disease areas; faster approval in Asia for some diseases areas may be related to country-level disease priorities.
• This analysis included Hong Kong, Japan, Singapore, and Indonesia as representing Asia, and the EU and US as representing the West. Further analysis would be needed to ascertain if this same trend would be observed with the inclusion of additional Asian or Western markets.
-Japan, Hong Kong and Singapore have a similar GDP per capita to that of the US and EU, compared to Indonesia which is much lower. This lower economic development was reflected in the number of marketing approvals in Indonesia.
-As the delay was strongly influenced by the lowest economically developed country (Indonesia), the inclusion of additional countries with lower economic status would be expected to lengthen the observed delay. -Compared to Singapore and Hong Kong, Japan also had a lower number of approvals, which may reflect the method of the study (searches of the Japan registrations were limited to 2004 onwards). The lower number of approvals could also be reflective of their more stringent approval process, requiring efficacy and safety data in Japanese patients (Singapore and Hong Kong do not have such requirements).
• Some important new therapies were absent from the analysis as they are yet to be approved in any of the four Asian countries included, such as recently launched sofosbuvir (Sovaldi; HCV) and elvitegravir/cobicistat/tenofovir/emtricitabine (Stribild; HIV-1).
-The lack of these newer therapies in the Asian markets studied indicates that delays to approval in Asia are still present. Figure 3. Sensitivity analysis of the correlation between year of first approval* and the delay between marketing approval in the West and Asia, excluding data from Indonesia.
• Regression analysis indicated that, despite the delay for RA drugs (mainly biological therapies) being considerably longer than that of the T2DM (all small molecules) in 2000 (5.4 vs 2.1 years), by 2013 the average delay for drugs in both indications was less than one year, due to a greater rate of decrease in the delay for RA approvals in Asia.
• Investigating the observed trend in drugs that were indicated for the treatment of HIV-1 demonstrated that the correlation was less strong (r=-0.56; p≤0.005; Spearman Rank correlation). Although there were too few included drugs indicated in only HBV/HCV to investigate the trend separately, the data for this follows qualitatively the trend seen for HIV-1 ( Figure 2B ).
• Analysing the trend using data points from all five disease areas found that the negative correlation between date of first marketing approval and the delay between marketing approval in the West and Asia was evident (r=-0.65; p<0.001; Spearman Rank correlation).
• The sensitivity analysis, excluding data from Indonesia, demonstrated that the negative correlation between date of first approval (in any included country) and delay in approval between Western and Asian markets was weaker when the less welldeveloped Asian country of Indonesia was not included (r=-0.37; p≤0.005; Spearman Rank correlation; Figure 3 ). 
